Bioline Rx (BLRX) closed at $1.71 on November 6, 2026, down 3.3% from the previous close, on volume of 7,756 shares (30-day average 13,266).
Data as of November 6, 2026.
6-Nov-2026
No headlines found.
PRNewswire (Fri, 23-Oct 7:01 AM ET)
PRNewswire (Thu, 8-Oct 7:01 AM ET)
PRNewswire (Thu, 10-Sep 7:00 AM ET)
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PRNewswire (Mon, 31-Aug 7:00 AM ET)
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
PRNewswire (Fri, 28-Aug 8:00 AM ET)
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
PRNewswire (Tue, 25-Aug 7:00 AM ET)
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Bioline Rx trades on the NASDAQ stock market under the symbol BLRX.
As of November 6, 2026, BLRX stock price declined to $1.71 with 7,756 million shares trading.
BLRX has a market cap of $8.51 million. This is considered a Sub-Micro Cap stock.
Last quarter Bioline Rx reported $294,000 in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-206,000 and exceeded earnings estimates by $.24.
In the last 3 years, BLRX traded as high as $77.20 and as low as $1.70.
BLRX has underperformed the market in the last year with a price return of -48.6% while the SPY ETF gained +10.8%. BLRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.7% and -16.2%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
BLRX support price is $1.65 and resistance is $1.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLRX shares will trade within this expected range on the day.
